8-K: Protagenic Therapeutics Amends At-the-Market Sales Agreement, Eyes $1.2 Million Offering

Protagenic Therapeutics amends its sales agreement with B. Riley Securities to facilitate a potential $1.2 million at-the-market offering of common stock.

Summary

• Protagenic Therapeutics, Inc. has amended its At Market Issuance Sales Agreement with B. Riley Securities, Inc. on January 9, 2025.
• The amendment, designated as Amendment No. 1, updates the original agreement dated July 2, 2021.
• The company may offer and sell shares of its common stock, with an aggregate offering price of up to $1,200,000, through B. Riley Securities.
• The company is not obligated to sell any shares under the agreement.
• B. Riley Securities will receive a commission of 3.0% of the gross sales price per share sold.
• The offering will be made pursuant to the company's shelf registration statement on Form S-3, which was declared effective on January 8, 2025.
• EF Hutton, division of Benchmark Investments, LLC was removed as a sales agent.

Sentiment

Score: 6

Explanation: The announcement is neutral to slightly positive. It provides the company with financial flexibility but also carries the risk of dilution.

Positives

• The amendment provides Protagenic Therapeutics with a flexible mechanism to raise capital through an at-the-market offering.
• The company is not obligated to sell any shares, providing control over the timing and amount of the offering.
• The shelf registration statement is already effective, allowing for a quick execution of the offering if desired.

Negatives

• The company will incur a 3.0% commission on the gross sales price for any shares sold through B. Riley Securities, reducing the net proceeds.
• The potential dilution of existing shareholders if the company chooses to sell a significant number of shares.

Risks

• The company's ability to sell shares under the agreement depends on market conditions and investor demand.
• There is no guarantee that the company will be able to sell all or any of the $1,200,000 worth of shares.
• The at-the-market offering could put downward pressure on the company's stock price.

Future Outlook

The company may offer and sell shares of its common stock from time to time through B. Riley Securities, but it is not obligated to do so.

Industry Context

At-the-market offerings are a common way for small-cap companies to raise capital, providing flexibility and control over the timing and amount of the offering.

Comparison to Industry Standards

• Comparable companies often use at-the-market offerings to raise capital, but the commission rate of 3.0% is within the typical range for such offerings.
• The size of the offering, $1.2 million, is relatively small compared to some other at-the-market offerings in the biotech industry, which can range from a few million to tens of millions of dollars.

Stakeholder Impact

• Shareholders may experience dilution if the company sells a significant number of shares.
• The company's employees and other stakeholders may benefit from the additional capital raised through the offering.

Next Steps

• The company may choose to offer and sell shares of its common stock through B. Riley Securities at its discretion.
• B. Riley Securities will use commercially reasonable efforts to sell the shares based on the company's instructions.

Key Dates